Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $344.5 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 0.76% year-over-year to $344.5 million in Q1 2026; TTM through Mar 2026 was $344.5 million, a 0.76% decrease from a year earlier, with the FY2025 full-year figure at $317.7 million, down 27.29% from the prior year.
• Total Non-Current Liabilities advanced to $344.5 million in Q1 2026 per ACAD's latest filing, from $317.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $436.9 million in Q4 2024 and bottomed at $170.3 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $317.7 million (2025), against an average of $302.9 million.
• Across the five-year window, Total Non-Current Liabilities surged 69.38% in 2023 and dropped 27.29% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $178.3 million in 2022, then jumped by 69.38% to $302.1 million in 2023, then soared by 44.65% to $436.9 million in 2024, then fell by 27.29% to $317.7 million in 2025, then rose by 8.46% to $344.5 million in 2026.
• Per Business Quant, the three latest ACAD Total Non-Current Liabilities figures stand at $344.5 million (Q1 2026), $317.7 million (Q4 2025), and $399.6 million (Q3 2025).